Reduction of complex ventricular ectopy and improvement in exercise capacity with flecainide therapy in Andersen-Tawil syndrome.

Abstract

Andersen-Tawil syndrome (ATS) is a rare inherited autosomal disorder characterized by the clinical triad of ventricular arrhythmias, hypokalaemic periodic paralyses, and skeletal developmental abnormalities, resulting in dysmorphic features. Although ATS patients have a high incidence of ventricular arrhythmias, the occurrence of sudden cardiac death is rare. In this report, we describe the successful use of flecainide in an ATS patient with a considerable ventricular arrhythmia burden who had not demonstrated any response to conventional beta-blocker therapy used in conjunction with potassium (K(+)) supplementation.

DOI: 10.1093/europace/eun180

Extracted Key Phrases

2 Figures and Tables

Cite this paper

@article{Fox2008ReductionOC, title={Reduction of complex ventricular ectopy and improvement in exercise capacity with flecainide therapy in Andersen-Tawil syndrome.}, author={David J Fox and George J . Klein and Angelika F G Hahn and Allan C. Skanes and Lorne J . Gula and Raymond K. Yee and Rajesh Subbiah and Andrew D . Krahn}, journal={Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology}, year={2008}, volume={10 8}, pages={1006-8} }